Yield10 Bioscience, Inc. Common Stock
YTEN
YTEN was delisted on the 15th of May, 2024.
7 hedge funds and large institutions have $1.64M invested in Yield10 Bioscience, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
40% more capital invested
Capital invested by funds: $1.17M → $1.64M (+$471K)
40% more funds holding
Funds holding: 5 → 7 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$605K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$441K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$197K |
| 4 |
Renaissance Technologies
New York
|
+$168K |
| 5 |
BC
Birchview Capital
Burlington,
Vermont
|
+$124K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
GMT Capital
Atlanta,
Georgia
|
-$107K |
YTEN Hedge Fund Activity: Q4 2017 in Review
7 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Yield10 Bioscience, Inc. Common Stock (YTEN) for Q4 2017, worth a combined $1.64M — up 40% from $1.17M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new YTEN positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $605K. The largest seller was GMT Capital, exiting entirely with an estimated $107K sold.
- 7 institutional investors held Yield10 Bioscience, Inc. Common Stock (YTEN) as of Q4 2017, up from 5 in Q3 2017.
- Funds reported $1.64M of Yield10 Bioscience, Inc. Common Stock stock for Q4 2017, up 40% quarter-over-quarter.
- 3 funds opened new Yield10 Bioscience, Inc. Common Stock positions in Q4 2017 and 1 closed out, a net change of +2 holders.
- The largest Yield10 Bioscience, Inc. Common Stock buyer in Q4 2017 was Sabby Management, an estimated $605K added.
- The largest Yield10 Bioscience, Inc. Common Stock seller in Q4 2017 was GMT Capital, an estimated $107K sold.
Based on aggregated 13F filings for Q4 2017.